Pharmacogenetics of alcohol and alcohol dependence treatment
about
Opioid therapy pharmacogenomics for noncancer pain: efficacy, adverse events, and costsThe role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical reviewDopamine D4 receptor gene DRD4 and its association with psychiatric disordersThe relationship of appetitive, reproductive and posterior pituitary hormones to alcoholism and craving in humansADHD and Present Hedonism: time perspective as a potential diagnostic and therapeutic toolEthanol withdrawal-induced motor impairment in miceAnimal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validityDSM-5 criteria for substance use disorders: recommendations and rationalePharmacogenetics of new analgesics.Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate.Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.The relationship between naloxone-induced cortisol and delta opioid receptor availability in mesolimbic structures is disrupted in alcohol-dependent subjectsVariation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.Medications development to treat alcohol dependence: a vision for the next decade.The relationship between naloxone-induced cortisol and mu opioid receptor availability in mesolimbic structures is disrupted in alcohol dependent subjects.Selection for drinking in the dark alters brain gene coexpression networks.Testing multiple levels of influence in the intergenerational transmission of alcohol disorders from a developmental perspective: the example of alcohol use promoting peers and μ-opioid receptor M1 variation.Using genetically engineered animal models in the postgenomic era to understand gene function in alcoholism.Introduction to the special issue "Pharmacotherapies for the treatment of alcohol abuse and dependence" and a summary of patents targeting other neurotransmitter systems.Variation in Mu-Opioid Receptor Gene (OPRM1) as a Moderator of Naltrexone Treatment to Reduce Heavy Drinking in a High Functioning Cohort.Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds.Subjective Response to Alcohol as a Research Domain Criterion.Association of V89L SRD5A2 polymorphism with craving and serum leptin levels in male alcohol addicts.Pharmacogenetics of alcoholism: a clinical neuroscience perspective.GRIK1 and GABRA2 Variants Have Distinct Effects on the Dose-Related Subjective Response to Intravenous Alcohol in Healthy Social Drinkers.Effects of automated smartphone mobile recovery support and telephone continuing care in the treatment of alcohol use disorder: study protocol for a randomized controlled trial.Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging.Real-time assessment of alcohol craving and naltrexone treatment responsiveness in a randomized clinical trial.
P2860
Q21284753-DE4C0588-2DBF-4AF1-BBC1-A5DBF7D69B10Q24616528-0016B56E-6928-4258-925A-2B886A5BD340Q24629051-F820F159-A4F9-4737-B7A7-8D8861C098CFQ26992207-F088CE7A-D8B8-4342-9FBE-3E09AC84470BQ28074594-D777D2B2-BD98-4841-B324-2702209B98A8Q30442184-95617929-AE4B-4E7C-B796-3916041595B9Q30447847-931D199F-0DAE-462A-8502-97E559629E84Q30544314-4A4059D9-4737-4235-A897-E82EA3C8815EQ35005640-74CDC752-CE88-4766-A8DB-FB37EB5093D6Q35150158-1706F7F6-93C1-468E-B649-16E6D306D78FQ35565599-312AE4AD-BFD4-4531-A476-D18B088EDB1BQ35916280-20E1014F-0D60-4E6E-8878-0884A58A6B12Q36322822-B435E17C-258D-4908-9648-850C1A56FB9CQ36357552-82E0906A-0C4A-42DB-A549-6CE9AE3FD05FQ37032709-81C081B8-2F0C-4666-8EB5-FCE7462E251BQ37137302-156D809E-43D2-4948-9223-35E4ACC9EED7Q37251218-215F32A4-BDF9-4572-A167-8AD274919BDBQ37386384-0CB310EB-1E3E-403D-BC49-809015E6BC96Q37404222-6DB35E18-487B-4092-87B3-D897D7F0A378Q37698510-6DF9AEA9-228B-476E-B223-6EC5A64072AFQ38003649-CCB1E693-2F73-41D5-8446-0324D1A58EC2Q38248763-635EE893-DDD5-4E7C-B7D5-E6E1842BAB06Q38685941-888A249F-0B9B-4920-A858-F917A1077946Q39601097-B20B4918-D8E5-46AA-92DE-E51B47909639Q42157163-17EE49D0-6DF2-4CF1-A6C1-88E21F5FF64CQ47616594-06A4262C-137C-4C17-865A-01121C43BC8FQ47703858-6968EB15-CEBD-4542-AEC9-59945E8A74A8Q48448207-7A576B01-87FF-40DE-94A6-FB53B2F15D6FQ50067452-549E9D33-BCD1-4377-ACFA-9ABDEF6F938A
P2860
Pharmacogenetics of alcohol and alcohol dependence treatment
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacogenetics of alcohol and alcohol dependence treatment
@ast
Pharmacogenetics of alcohol and alcohol dependence treatment
@en
Pharmacogenetics of alcohol and alcohol dependence treatment
@nl
type
label
Pharmacogenetics of alcohol and alcohol dependence treatment
@ast
Pharmacogenetics of alcohol and alcohol dependence treatment
@en
Pharmacogenetics of alcohol and alcohol dependence treatment
@nl
prefLabel
Pharmacogenetics of alcohol and alcohol dependence treatment
@ast
Pharmacogenetics of alcohol and alcohol dependence treatment
@en
Pharmacogenetics of alcohol and alcohol dependence treatment
@nl
P2860
P1476
Pharmacogenetics of alcohol and alcohol dependence treatment
@en
P2093
Henry R Kranzler
P2860
P304
P356
10.2174/138161210791516387
P577
2010-01-01T00:00:00Z